Literature DB >> 12906106

Overcoming tolerance in hepatitis B virus transgenic mice: a possible involvement of regulatory T cells.

Sujin Roh1, Kilhyoun Kim.   

Abstract

The hepatitis B virus (HBV) transgenic mouse (Tg) 50-4 strain is immunologically tolerant to HBV antigens. Various vaccination strategies have been attempted but failed to break the tolerance in the mouse. Although the tolerance to HBV antigen is maintained, this mouse strain develops spontaneous liver disease beginning at the age of about 3 months. We attempted to induce immune responses to HBV surface antigen (HBsAg) in the Tg by immunization with recombinant vaccinia virus expressing HBsAg (vvHBV), and observed different immunological responsiveness between 2-month-old and 5-month-old Tg. In contrast to the unbreakable tolerance reported previously, we could induce both the cytotoxic T lymphocyte (CTL) and the antibody response against HBsAg by the vvHBV immunization. The cytokine expression pattern indicated that T helper 1 type immune response was induced. However, interestingly, these immune responses were observed only in the 5-month-old Tg, but not in the 2-month-old Tg. Furthermore, CD4+ T cells from 2-month-old mice, but not those from 5-month-old mice, inhibited CTL response to HBV antigen when adoptively transferred to C57BL/6. These results suggest the possible involvement of regulatory T cell function in the HBV Tg for maintaining tolerance. This study would contribute to a better understanding of immune status of the HBV Tg as a model of human chronic hepatitis and to the search for new therapeutic targets for chronic viral infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12906106     DOI: 10.1111/j.1348-0421.2003.tb03370.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  5 in total

1.  Identification of a unique double-negative regulatory T-cell population.

Authors:  Byung O Lee; Joyce E Jones; Cory J Peters; David Whitacre; Lars Frelin; Janice Hughes; Won-Keun Kim; David R Milich
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

2.  Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo.

Authors:  Xiaohua Chen; Yuyan Tang; Yi Zhang; Meng Zhuo; Zhenghao Tang; Yongsheng Yu; Guoqing Zang
Journal:  Lab Invest       Date:  2014-03-10       Impact factor: 5.662

Review 3.  Molecular characteristics and stages of chronic hepatitis B virus infection.

Authors:  Ying-Hui Shi; Chang-He Shi
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

4.  Plasmacytoid Dendritic Cell Function and Cytokine Network Profiles in Patients with Acute or Chronic Hepatitis B Virus Infection.

Authors:  Ming-Hui Li; Lu Zhang; Dan Zhang; Wei-Hua Cao; Tian-Lin Qi; Hong-Xiao Hao; Xing-Yue Wang; Chong-Ping Ran; Xiao-Jing Qu; Shun-Ai Liu; Yao Lu; Ge Shen; Shu-Ling Wu; Min Chang; Ru-Yu Liu; Lei-Ping Hu; Wen-Hao Hua; Gang Wan; Jun Cheng; Yao Xie
Journal:  Chin Med J (Engl)       Date:  2018-01-05       Impact factor: 2.628

5.  Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection.

Authors:  Yasuteru Kondo; Masashi Ninomiya; Eiji Kakazu; Osamu Kimura; Tooru Shimosegawa
Journal:  ISRN Gastroenterol       Date:  2013-01-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.